• KOL
    • National Cancer Institute
    • Elizabeth A Eisenhauer
    • Elizabeth A Eisenhauer: Influence Statistics

      Elizabeth A Eisenhauer

      Elizabeth A Eisenhauer

      Show email address

      Department of Oncology, Queen's University, Kingston, Canada | Department of Oncology, Queen's University, Kingston, ON, Canada. | Department of Oncology, School of Medicine, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Elizabeth A Eisenhauer:Expert Impact

      Concepts for whichElizabeth A Eisenhauerhas direct influence:National cancer institute,Ovarian cancer,Canada clinical trials,Ncic ctg,Task force,Ncic clinical trials.

      Elizabeth A Eisenhauer:KOL impact

      Concepts related to the work of other authors for whichfor which Elizabeth A Eisenhauer has influence:Ovarian cancer,Cell lung,Neoadjuvant chemotherapy,Solid tumors,Antineoplastic agents,Glioblastoma multiforme,Elderly patients.

      KOL Resume for Elizabeth A Eisenhauer

      Year
      2022

      Department of Oncology, Queen's University, Kingston, Canada

      2021

      Departments of Oncology, Queen’s University, Kingston, Canada

      2020

      Queen's University, Kingston, Canada

      2018

      Department of Oncology, Queen's University, Kingston, Ontario, Canada

      2017

      Department of Oncology, Queen's University, Kingston Health Sciences Centre, Kingston, Canada.

      Canadian Cancer Trials Group (CCTG), Queen’s University, Kingston, Canada;

      Queen’s University and Cancer Centre of South Eastern Ontario at Kingston General Hospital, Kingston, ON Canada

      2016

      Canadian Cancer Trials Group (CCTG) and Queen's University, Kingston, ON, Canada

      Department of Oncology, Queen's University, Kingston, ON.

      2015

      NCIC Clinical Trials Group, Kingston, ON, Canada

      2014

      NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada

      2013

      NCIC Clinical Trials Group, Queen's University, 10 Stuart St, Kingston, Ontario K7L 3N6, Canada

      2012

      Department of Medical Oncology, Queen's University, Kingston, Canada

      NCIC Clinical Trials Group, Kingston, Ontario

      2011

      NCIC Clinical Trials Group, Queen's University, Kingston, Ontario

      National Cancer Institute of Canada Clinical Trials Group, Queen’s University, Kingston, Canada

      S, *, BIO Pte Ltd, 1 Science Park Road, #05-09 The Capricorn, Singapore Science Park II, 117 528, Singapore

      2010

      National Cancer Institute of Canada Clinical Trials Group, Kingston

      University of Montreal, Montreal, Quebec, Canada

      Tom Baker Cancer Centre, Calgary

      Princess Margaret Hospital, Toronto, Ontario

      Vancouver Prostate Centre, Vancouver, British Columbia

      2009

      and Saitama Medical University, Hidaka City, Saitama, Japan.

      National Cancer Institue of Canada, Clinical Trials Group, Kingston, Ontario, Canada

      University of New South Wales, Sydney, New South Wales, Australia

      GlaxoSmithKline Biologicals, Rixensart, Belgium

      Medical Research Council Clinical Trials Unit, London

      2008

      From the Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD

      and Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA

      National Cancer Institute of Cancer Clinical Trials Group, Queen's University, Kingston, Ontario, Canada

      Southwest Oncology Group Statistical Office, Seattle, WA

      Peace Corps, Washington, DC

      2007

      Eastern Cooperative Oncology Group, Philadelphia, PA

      NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada.

      National Cancer Institute of Canada Clinical Trials Group, Queen’s University, 10 Stuart Street, Kingston, ON, Canada K7L 3N6

      Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia

      From the Princess Margaret Hospital, Toronto

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Elizabeth A Eisenhauer is among the top experts in the world.
      Concept World rank
      oral pracinostat tiw #1
      small cell deoxycytidine #1
      topic recist #1
      ncicctg antineoplastic agents #1
      83 116 cycles #1
      tumourcentred definition 95 #1
      ly293111 dlt #1
      trials cytotoxic #1
      toxicity drug dose #1
      response pten #1
      toxicity treatment discontinuation #1
      letrozole disease progression #1
      studies canadian sarcoma #1
      phase osi211 #1
      sb939 objective responses #1
      curve dna cytosine5methyltransferase #1
      cycles sequential couplets #1
      teloxantrone #1
      cisplatin arm cyclophosphamide #1
      reporting benefit #1
      dose levels dlt #1
      ca125 progression endpoint #1
      women toxic effects #1
      cyclophosphamide cisplatin arm #1
      strict progression #1
      trimetrexate malignant melanoma #1
      45 adult dose #1
      cohort 30 μg #1
      response evaluation model #1
      continual validation #1
      rpr 109881a #1
      non‐cytotoxics #1
      schedule osi211 #1
      dlt doses #1
      solid tumors guidelines #1
      response preliminary #1
      cancer treatment oncology #1
      menogaril dose 225 #1
      amsterdam phase #1
      265months #1
      myeloma indolent lymphomas #1
      doselimiting toxicity acivicin #1
      cb endpoint #1
      ncic ind161 #1
      everolimus tmz #1
      225 4 #1
      rptd 5 consecutive #1
      chose trade #1
      definition toxicity #1
      1 sb939 #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Elizabeth A Eisenhauer

      KOL-Index: 18224

      BACKGROUND: Angiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1-3 inhibitor that has shown antitumour activity in recurrent ovarian cancer. We assessed efficacy and safety of cediranib in combination with platinum-based chemotherapy and as continued maintenance treatment in patients with first relapse of platinum-sensitive ovarian cancer.

      METHODS: In this randomised, ...

      Known for Ovarian Cancer | 3 Trial | Chemotherapy Cediranib | Arm Maintenance | Local Neoplasms
      KOL-Index: 17384

      BACKGROUND: A randomised trial published by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group (trial 26981-22981/CE.3) showed that addition of temozolomide to radiotherapy in the treatment of patients with newly diagnosed glioblastoma significantly improved survival. We aimed to undertake an exploratory subanalysis of the EORTC and NCIC data to confirm or identify new prognostic factors for ...

      Known for Radiotherapy Temozolomide | Ncic Trial | Newly Diagnosed Glioblastoma | Performance Status | Combined Treatment
      KOL-Index: 16475

      BACKGROUND: In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy. We report the final results with a median follow-up of more than 5 years.

      METHODS: Adult patients with newly diagnosed glioblastoma were randomly assigned ...

      Known for Adjuvant Temozolomide | 5 Years | Radiotherapy Survival | Eortc Ncic | Phase Iii
      KOL-Index: 16144

      BACKGROUND: Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a novel combination compared with standard frontline therapy.

      METHODS: Women aged 75 years or younger with newly diagnosed stage IIB or greater ovarian cancer, Eastern Cooperative Oncology Group Performance Status of 1 or less, were stratified by type of primary surgery and residual disease, treatment center, and age; then randomly assigned to one of the two 21-day intravenous regimens. ...

      Known for Paclitaxel Carboplatin | Advanced Ovarian Cancer | Patients Arm | Neoplasm Female Humans | Phase Iii
      KOL-Index: 16076

      BACKGROUND: Early endometrial cancer with low-risk pathological features can be successfully treated by surgery alone. External beam radiotherapy added to surgery has been investigated in several small trials, which have mainly included women at intermediate risk of recurrence. In these trials, postoperative radiotherapy has been shown to reduce the risk of isolated local recurrence but there is no evidence that it improves recurrence-free or overall survival. We report the findings from ...

      Known for External Beam Radiotherapy | Endometrial Cancer | Ncic Ctg | Mrc Astec | Intermediate Risk
      KOL-Index: 14091

      PURPOSE: Most patients with advanced ovarian cancer develop recurrent disease. For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel; however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation. Thus, an alternative regimen without significant neurotoxicity was evaluated by comparing gemcitabine plus carboplatin with ...

      Known for Carboplatin Patients | Sensitive Recurrent | Ovarian Cancer | Ncic Ctg | Quality Life
      KOL-Index: 13891

      BACKGROUND: Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials. Since RECIST was published in 2000, many investigators, cooperative groups, industry and government authorities have adopted these criteria in the assessment of treatment outcomes. However, a number of questions and issues have arisen which have led to ...

      Known for Revised Recist | New Response | Tumour Burden | Sum Lesions | Special Issue
      KOL-Index: 13737

      BACKGROUND: Pemetrexed disodium (Alimta [Eli Lilly and Company, Indianapolis, IN], LY231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. Phase II trials showed single-agent response rates of 16% and 23% in untreated patients with nonsmall cell lung carcinoma (NSCLC). This study was undertaken to determine the response to pemetrexed disodium given in combination with cisplatin.

      METHODS: Previously untreated ...

      Known for Pemetrexed Disodium | Multitargeted Antifolate | Performance Status | Cell Lung | Nsclc Study
      KOL-Index: 13714

      AIM: The impact of PTEN status and microsatellite instability (MSI) on the prognosis of women with endometrial cancer is controversial. The aim of this study was to investigate MSI and PTEN expression in two patient populations using data from NCIC CTG studies.

      METHODS: Archival paraffin embedded tumour from women with endometrial cancer enrolled in NCIC CTG studies: EN5 (stage I/II) and IND 126, 148 and 160 (advanced/recurrent disease) were examined for MSI using BAT25/26 and for PTEN ...

      Known for Microsatellite Instability | Pten Expression | Endometrial Cancer | Msi Status | Ncic Clinical Trials
      KOL-Index: 13615

      BACKGROUND: Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety.

      METHODS: Patients with newly diagnosed, histologically confirmed glioblastoma were ...

      Known for Adjuvant Temozolomide | Patients Radiotherapy | 5 Week | Square Meter | Primary Point
      KOL-Index: 12746

      Prolonged exposure to a topoisomerase I inhibitor may increase expression of topoisomerase II, making cells more susceptible inhibitors of that enzyme. This study was undertaken to establish the maximum tolerated dose (MTD) of a topotecan/topoisomerase II inhibitor sequential combination that may be active in acute leukemia, and to evaluate the effects of in vivo exposure to topotecan on topoisomerase II levels in leukemic blast cells as measured by image cytometry. Patients who were ...

      Known for Sequential Topotecan | Acute Leukemia | National Cancer Institute | Patients Phase | Dose Levels
      KOL-Index: 12686

      BACKGROUND: A randomised controlled trial of radiotherapy alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma showed that survival was higher for patients assigned combination treatment compared with those assigned standard radiotherapy alone. This paper reports the health-related quality of life (HRQOL) of the patients in this trial.

      METHODS: 573 patients with newly diagnosed glioblastoma were randomly allocated either radiotherapy alone ...

      Known for Radiotherapy Patients | Life Hrqol | Controlled Trial | Healthrelated Quality | Newly Diagnosed Glioblastoma
      KOL-Index: 11694

      BACKGROUND: Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment resistance. OGX-011 is a 2'-methoxyethyl modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA and has been reported to inhibit clusterin expression and enhance drug efficacy in xenograft models. The primary objective of this clinical study was to determine a biologically effective dose of OGX-011 that would inhibit clusterin ...

      Known for Localized Prostate Cancer | Clusterin Expression | Pharmacodynamic Study | Antisense Oligonucleotide | Dose Ogx011
      KOL-Index: 10756

      PURPOSE: Formal quality-of-life (QOL) assessments may contribute important information on patient symptoms. Despite many trials of systemic chemotherapy in ovarian cancer, reports of its effect on QOL are few.

      PATIENTS AND METHODS: QOL was assessed in an Intergroup randomized trial comparing paclitaxel plus cisplatin to cyclophosphamide plus cisplatin in women with advanced ovarian cancer. One hundred fifty-two eligible patients accrued in Canada completed the European Organization for ...

      Known for Ovarian Cancer | Paclitaxel Cisplatin | Qol Patients | Quality Life | European Organization

      Key People For National Cancer Institute

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Robert H Shoemaker
      cell lines multidrug resistance checkpoint kinase
      #3
      Michael R Boyd
      antineoplastic agents cell lines covalent binding
      #4
      Kenneth D Paull
      cell lines national cancer institute benzamide riboside
      #5
      Anne P Monks
      cell lines national cancer institute gene expression
      #6
      Dominic A Scudiero
      cell lines national cancer institute colon cancer

      Department of Oncology, Queen's University, Kingston, Canada | Department of Oncology, Queen's University, Kingston, ON, Canada. | Department of Oncology, School of Medicine, Faculty of Health Sciences, Queen’s University, Kingston, Ontario, Canada |

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.